AstraZeneca's Imfinzi granted priority review in the US
4th May 2022 07:42
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that a supplemental biologics license application for its Imfinzi asset, in combination with standard-of-care chemotherapy, had been accepted and granted priority review in the US for patients with locally advanced or metastatic biliary tract cancer.
Read moreAstraZeneca reiterates guidance after first quarter growth
29th Apr 2022 08:23
(Sharecast News) - AstraZeneca said on Friday that its total revenue for the first quarter surged 60% to $11.39bn (£9.07bn), with growth across the company seeing it reiterate its full-year guidance.
Read moreAstrazeneca's Ultomiris receives FDA approval
28th Apr 2022 09:16
(Sharecast News) - Drugmaker AstraZeneca's Ultomiris asset has been approved in the US for adults with generalised myasthenia gravis.
Read moreAstraZeneca's Enhertu granted FDA breakthrough therapy designation
27th Apr 2022 08:34
(Sharecast News) - Drugmaker AstraZeneca's Enhertu candidate has been granted breakthrough therapy designation in the US for adult patients with HER2-low metastatic breast cancer.
Read moreFDA accepts priority review application for AstraZeneca's tremelimumab
25th Apr 2022 07:28
(Sharecast News) - Drugmaker AstraZeneca said on Monday that an application for priority review of its tremelimumab asset had been accepted by the US Food and Drug Administration.
Read moreAstraZeneca's Enhertu to be reviewed by FDA following DESTINY-Lung01 trial
19th Apr 2022 08:05
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Enhertu candidate had been granted priority review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.
Read moreBerenberg raises target price on AstraZeneca
12th Apr 2022 10:18
(Sharecast News) - Analysts at Berenberg raised their target price on AstraZeneca shares from £100 to £120 on Tuesday, stating the stock was now "hot to trop".
Read moreJP Morgan ups AstraZeneca target price on potential for oncology pipeline
7th Apr 2022 14:27
(Sharecast News) - Analysts at JP Morgan hiker their target price for shares of AstraZeneca and pointed to the potential for "significant" future upward revisions to analysts' estimates for the profitability of the company's oncology pipeline.
Read moreDeutsche Bank hikes AstraZeneca target price despite rising rate environment
6th Apr 2022 11:07
(Sharecast News) - Analysts at Deutsche Bank hiked their target price for shares of AstraZeneca, telling clients they saw no reason to tilt towards so-called 'value' names in the space and away from 'growth'.
Read moreAstraZeneca's Ondexxya receives Japanese approval
29th Mar 2022 07:14
(Sharecast News) - Drugmaker AstraZeneca revealed on Tuesday that its Ondexxya asset had become the first approved medicine in Japan to specifically reverse the anticoagulant effect of Factor Xa inhibitors, providing "a major advance" in the treatment of patients hospitalised with life-threatening bleeding.
Read moreAstraZeneca Covid drug gets EU approval
28th Mar 2022 07:19
(Sharecast News) - The European Union has given marketing approval to AstraZeneca's Evusheld coronavirus medicine for adults and children over 12 years old, the company said on Monday.
Read moreAstraZeneca's Imfinzi shows no major cervical cancer benefit
24th Mar 2022 08:13
(Sharecast News) - AstraZeneca said its Imfinzi treatment did not produce a significant improvement for cervical cancer patients over treatment by chemoradiotherapy (CRT) on its own.
Read moreAstraZeneca enters into settlement agreement with Chugai Pharmaceutical
17th Mar 2022 07:58
(Sharecast News) - Drugmaker AstraZeneca's rare disease unit has entered into a settlement agreement with Chugai Pharmaceutical, resolving all patent disputes between the two companies related to long-acting C5 complement inhibitor, Ultomiris (ravulizumab).
Read moreAstraZeneca's Lynparza candidate gets green light from FDA
14th Mar 2022 07:37
(Sharecast News) - Drugmaker AstraZeneca said on Monday that Lynparza candidate had been approved in the US as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.
Read moreAstraZeneca strikes global collaboration and licence agreement with Neurimmune
1st Mar 2022 07:51
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its rare diseases subsidiary had closed an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development.
Read more